Data gathered: October 26
Alternative Data for Immunitybio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 28 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 33,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 74 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,382 | Sign up | Sign up | Sign up |
| Reddit Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 564 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,280 | Sign up | Sign up | Sign up |
| Twitter Followers | 12,296 | Sign up | Sign up | Sign up |
| Twitter Mentions | 44 | Sign up | Sign up | Sign up |
| X Mentions | 44 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 586 | Sign up | Sign up | Sign up |
About Immunitybio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
| Price | $2.47 |
| Target Price | Sign up |
| Volume | 10,620,000 |
| Market Cap | $2.43B |
| Year Range | $1.89 - $3.9 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Voya Investment Management LLC Trims Stock Holdings in ImmunityBio, Inc. $IBRXOctober 2 - ETF Daily News |
 |
ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC ExpansionOctober 1 - Yahoo |
|
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer PatientsSeptember 19 - Yahoo |
|
HC Wainwright Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)September 11 - ETF Daily News |
|
D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)September 9 - ETF Daily News |
|
Hsbc Holdings PLC Grows Stake in ImmunityBio, Inc. $IBRXSeptember 7 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 26M | 140,000 | 26M | -93M | -60M | -0.100 |
| Q1 '25 | 17M | 58,000 | 16M | -130M | -64M | -0.150 |
| Q4 '24 | 7.6M | 4.1M | 7.6M | -59M | -17M | -0.080 |
| Q3 '24 | 6.1M | 150,000 | 6.1M | -86M | -41M | -0.123 |
| Q2 '24 | 1M | 4.4M | 1M | -135M | -91M | -0.200 |
Insider Transactions View All
| BLASZYK MICHAEL D filed to buy 71,915 shares at $2.8. June 5 '23 |
| BLASZYK MICHAEL D filed to buy 23,430 shares at $2.7. June 5 '23 |
| BLASZYK MICHAEL D filed to buy 71,430 shares at $2.8. June 5 '23 |
| Brennan John Owen filed to buy 5,000 shares at $2.7. June 5 '23 |
Similar companies
Read more about Immunitybio (IBRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Immunitybio?
The Market Cap of Immunitybio is $2.43B.
What is the current stock price of Immunitybio?
Currently, the price of one share of Immunitybio stock is $2.47.
How can I analyze the IBRX stock price chart for investment decisions?
The IBRX stock price chart above provides a comprehensive visual representation of Immunitybio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immunitybio shares. Our platform offers an up-to-date IBRX stock price chart, along with technical data analysis and alternative data insights.
Does IBRX offer dividends to its shareholders?
As of our latest update, Immunitybio (IBRX) does not offer dividends to its shareholders. Investors interested in Immunitybio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Immunitybio?
Some of the similar stocks of Immunitybio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
